Gene therapy to treat cardiovascular disease.
作者信息
Wolfram Julie A, Donahue J Kevin
机构信息
Department of Medicine, MetroHealth Campus of Case Western Reserve University, Cleveland, OH.
出版信息
J Am Heart Assoc. 2013 Aug 20;2(4):e000119. doi: 10.1161/JAHA.113.000119.
Abstract
摘要
相似文献
1
Gene therapy to treat cardiovascular disease.
J Am Heart Assoc. 2013 Aug 20;2(4):e000119. doi: 10.1161/JAHA.113.000119.
2
Site-specific gene therapy for cardiovascular disease.
Curr Opin Drug Discov Devel. 2010 Mar;13(2):203-13.
3
Gene therapy for cardiovascular disease.
Curr Opin Pharmacol. 2001 Apr;1(2):197-202. doi: 10.1016/s1471-4892(01)00027-3.
4
Gene therapy approaches to cardiovascular disease.
Methods Mol Med. 2005;112:15-35. doi: 10.1385/1-59259-879-x:015.
5
Novel vectors for in vivo gene delivery to vascular tissue.
Expert Opin Biol Ther. 2007 Jun;7(6):809-21. doi: 10.1517/14712598.7.6.809.
6
Method of gene delivery in large animal models of cardiovascular diseases.
Methods Mol Biol. 2011;709:355-67. doi: 10.1007/978-1-61737-982-6_23.
7
Gene therapy in cardiovascular surgery.
Surg Today. 1998;28(2):125-8. doi: 10.1007/s005950050092.
8
Ten steps to gene therapy for cardiovascular diseases.
J Lab Clin Med. 1998 Aug;132(2):104-11. doi: 10.1016/s0022-2143(98)90005-1.
9
The emerging role of gene therapy in the treatment of cardiovascular diseases.
Crit Rev Clin Lab Sci. 2003 Oct;40(5):499-545.
10
Gene therapy in the cardiovascular system: an update.
Cardiovasc Res. 1999 Dec;44(3):498-506. doi: 10.1016/s0008-6363(99)00259-x.
引用本文的文献
1
Gene Therapy for Cardiac Arrhythmias: Mechanisms, Modalities and Therapeutic Applications.
Med Sci (Basel). 2025 Jul 30;13(3):102. doi: 10.3390/medsci13030102.
2
Cell Reprogramming, Transdifferentiation, and Dedifferentiation Approaches for Heart Repair.
Int J Mol Sci. 2025 Mar 27;26(7):3063. doi: 10.3390/ijms26073063.
3
Tissue engineering with targeted delivery of nanotized S-nitrosyl mutant of NEMO ameliorates myocardial infarction.
Nanomedicine (Lond). 2025 May;20(10):1085-1099. doi: 10.1080/17435889.2025.2491989. Epub 2025 Apr 16.
4
Enhancing Cardiomyocyte Purity through Lactate-Based Metabolic Selection.
Tissue Eng Regen Med. 2025 Feb;22(2):249-260. doi: 10.1007/s13770-024-00696-4. Epub 2025 Jan 17.
5
Assessment of adeno-associated virus purity by capillary electrophoresis-based western.
Mol Ther Methods Clin Dev. 2024 Aug 14;32(3):101321. doi: 10.1016/j.omtm.2024.101321. eCollection 2024 Sep 12.
6
Cardiac gene delivery using ultrasound: State of the field.
Mol Ther Methods Clin Dev. 2024 Jun 4;32(3):101277. doi: 10.1016/j.omtm.2024.101277. eCollection 2024 Sep 12.
7
Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration.
J Cardiovasc Dev Dis. 2024 Jan 26;11(2):38. doi: 10.3390/jcdd11020038.
8
Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders.
Curr Gene Ther. 2024;24(5):356-376. doi: 10.2174/0115665232268840231222035423.
9
Modern medical services, a double-edged sword manages symptoms, but accumulates genetic background of cardiovascular diseases: A cross populational analysis of 217 countries.
Health Sci Rep. 2024 Jan 22;7(1):e1828. doi: 10.1002/hsr2.1828. eCollection 2024 Jan.
10
Three-dimensional heart extracellular matrix enhances chemically induced direct cardiac reprogramming.
Sci Adv. 2022 Dec 14;8(50):eabn5768. doi: 10.1126/sciadv.abn5768.
本文引用的文献
1
Gene therapy for cardiovascular disease mediated by ultrasound and microbubbles.
Cardiovasc Ultrasound. 2013 Apr 17;11:11. doi: 10.1186/1476-7120-11-11.
2
Janus-like role of fibroblast growth factor 2 in arteriosclerotic coronary artery disease: atherogenesis and angiogenesis.
Atherosclerosis. 2013 Jul;229(1):10-7. doi: 10.1016/j.atherosclerosis.2013.03.013. Epub 2013 Mar 26.
3
An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure.
Circ Res. 2013 Mar 1;112(5):816-25. doi: 10.1161/CIRCRESAHA.111.300440. Epub 2013 Feb 21.
4
Noncanonical EF-hand motif strategically delays Ca2+ buffering to enhance cardiac performance.
Nat Med. 2013 Mar;19(3):305-12. doi: 10.1038/nm.3079. Epub 2013 Feb 10.
5
HCN2/SkM1 gene transfer into canine left bundle branch induces stable, autonomically responsive biological pacing at physiological heart rates.
J Am Coll Cardiol. 2013 Mar 19;61(11):1192-201. doi: 10.1016/j.jacc.2012.12.031. Epub 2013 Feb 6.
6
Flushing out antibodies to make AAV gene therapy available to more patients.
Mol Ther. 2013 Feb;21(2):269-71. doi: 10.1038/mt.2013.5.
7
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association.
Circulation. 2013 Jan 1;127(1):143-52. doi: 10.1161/CIR.0b013e318282ab8f.
8
Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.
Mol Ther. 2013 Feb;21(2):318-23. doi: 10.1038/mt.2012.258. Epub 2012 Dec 18.
9
Heart disease and stroke statistics--2013 update: a report from the American Heart Association.
Circulation. 2013 Jan 1;127(1):e6-e245. doi: 10.1161/CIR.0b013e31828124ad. Epub 2012 Dec 12.
10
Connexin43 gene transfer reduces ventricular tachycardia susceptibility after myocardial infarction.
J Am Coll Cardiol. 2012 Sep 18;60(12):1103-10. doi: 10.1016/j.jacc.2012.04.042. Epub 2012 Aug 8.
Zotero 插件